Lazarus Labs Announces the Release of a Revolutionary New Appetite Suppressant

An exciting new breakthrough in weight control. Lazarus Labs, a leader in non-prescription pharmaceuticals, announced the release of Acompliex ™, an appetite suppressant clinically proven to reduce appetite by up to 38%.

Atlanta, GA (PRWEB) February 21, 2007 -- An exciting new breakthrough in weight control was announced today with the release of a non-prescription appetite suppressant trade-named Acompliex™. A spokesperson for Lazarus Labs, a non-prescription pharmaceutical company, said Acompliex™ was formulated in response to the alarming increase in overweight and obesity in the United States and other countries.

It is estimated that over 2/3 of the population of the United States is overweight or obese. Overweight and obesity are responsible for a number of serious health related risks and problems, including coronary heart disease, diabetes, high blood pressure, stroke, gallbladder disease, osteoarthritis, respiratory problems and even some types of cancer.

According to Arley Vest, CEO of Lazarus Labs, Acompliex ™ is a pharmaceutical grade non-prescription product designed to suppress appetite by a unique dual function which includes blocking neurotransmitters in the brain that trigger cravings for food as well as stimulating the release of the hunger suppressing hormone cholecystokinin (CCK) and the glucagon like peptide GLP1, which act to send a "full" feeling to the brain, thereby further decreasing the desire to eat - all without causing any stimulatory effects or dangerous side effects.

For more information, visit www.lazlabs.com or www.lazaruslabs.com or phone 770-606-1002.

###